As the calendar turned from April to May, a big change came to the FDA. Vinay Prasad, M.D., director of the Center for Biologics Evaluation and Research, officially departed from the agency for the ...

The revolving door at the Food and Drug Administration has pushed out another top official: Vinay Prasad, the controversial head of the agency’s vaccine and gene therapy arm, will depart in April.

The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions ...

Food and Drug Administration (FDA) Commissioner Marty Makary on Friday announced that the agency’s top regulator Vinay Prasad will depart next month. “A year ago, Dr. Prasad came to the FDA to ...

Homeland Security Secretary Kristi Noem is out, as Donald Trump names Markwayne Mullin to replace her. Will the DHS personnel change also affect ICE policy? Plus, does the U.S. have enough air-defense ...

The nation’s controversial top vaccine regulator is leaving his job at the end of April, federal health officials said Friday. Vinay Prasad had begun his role leading vaccines and complex treatments ...

Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval. By Christina Jewett Dr. Vinay Prasad, a polarizing figure at the Food and ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

Successor to be named before Prasad's departure Prasad had received criticism for his division's handling of rare disease treatments Prasad to return to UCSF March 6 (Reuters) - The controversial head ...

Editor's Note: This is a developing story. Please check back for updates. After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post ...

Aside from creating a toxic work environment, CBER Director Vinay Prasad has also been accused of berating his staff and retaliating against reviewers who questioned his decisions. The FDA is ...